3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Thrombocytopenia
3
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Leukemia, Myeloid, Acute
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Interventions
Cyclophosphamide
63
fludarabine phosphate
52
Busulfan
48
Cyclosporine
37
Antilymphocyte Serum
36
Peripheral Blood Stem Cell Transplantation
35
Cytarabine
29
Filgrastim
28
Mycophenolic Acid
27
Whole-Body Irradiation
26
Radiotherapy
26
Melphalan
26
Cord Blood Stem Cell Transplantation
24
Tacrolimus
23
Methotrexate
23
Methylprednisolone
21
fludarabine
19
Etoposide
16
Thiotepa
11
Granulocyte Colony-Stimulating Factor
11
Azacitidine
10
Alemtuzumab
9
Daunorubicin
8
sargramostim
7
Idarubicin
7
Decitabine
7
Biopsy
7
Topotecan
6
Stem Cell Transplantation
6
Mitoxantrone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Tranexamic Acid
×
Classical hematology
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled